[go: up one dir, main page]

WO2002102417A1 - Vecteur et son utilisation dans des procedes de therapie genique - Google Patents

Vecteur et son utilisation dans des procedes de therapie genique Download PDF

Info

Publication number
WO2002102417A1
WO2002102417A1 PCT/EP2002/006234 EP0206234W WO02102417A1 WO 2002102417 A1 WO2002102417 A1 WO 2002102417A1 EP 0206234 W EP0206234 W EP 0206234W WO 02102417 A1 WO02102417 A1 WO 02102417A1
Authority
WO
WIPO (PCT)
Prior art keywords
plasmid vector
vector according
nucleotide sequence
gene
plasmid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/006234
Other languages
German (de)
English (en)
Inventor
Jochen Reiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2002102417A1 publication Critical patent/WO2002102417A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Definitions

  • the present invention relates to a vector, in particular a plasmid vector for gene therapy purposes, in particular for somatic gene therapy, pharmaceutical compositions containing this plasmid vector and uses and methods using this plasmid vector.
  • Gene therapy methods are methods for correcting hereditary diseases using genetic engineering methodology by replacing one or more defective genes, by additionally introducing the normal gene or by introducing a gene which compensates for the effect of the defective gene.
  • Gene therapy methods are currently still in the experimental stage on animals.
  • germline gene therapy In the course of germline gene therapy, the genetic defect in the early embryonic stage is remedied, so that the germ cells of the individual are also affected and the changed genetic information is passed on to the offspring.
  • Somatic gene therapy eliminates genetic defects solely in organisms developed in the body cells, for example by transmitting a gene that has normal function. The genetic material passed on to the offspring therefore still contains the genetic defect.
  • the body cells to be treated are first removed from the body, finally, the desired genetic changes in the cells are carried out in vitro, and as a rule selected cells transformed by transforming the target cells with the gene used for gene therapy and then reimplanted in the patient.
  • a prerequisite is also the provision of the largest possible number of cells transformed with the desired gene.
  • the transformation that is to say the introduction of genetic material into the cells, usually takes place by means of chemical-physical methods, for example microinjection of DNA, or by using vectors, for example retroviruses, adenoviruses, herpes simplex viruses, DNA-containing liposomes or plasmid vectors.
  • viral vectors are known which are proposed for use in gene therapy processes and are capable of generating genetics Introduce material into target cells.
  • Polymeric gene carriers are known from WO 99/59546 which can introduce nucleic acids into cells.
  • WO 98/40502 describes peptide- or protein-containing compositions which, in addition to a transfection agent, also contain nucleic acids and can be used for gene therapy processes.
  • US 5,804,604 and US 5,674,980 describe the use of a plasmid for therapeutic purposes.
  • This plasmid encodes a fusion protein, comprising a basic region of the HIV-TAT transport protein (HIV: human immunodeficiency virus) and the Papillo avirus E2 repressor.
  • the fusion protein formed from the TAT transport protein part and the E2 repressor protein serves as a transport vehicle for the introduction of peptides, macromolecules or smaller molecules such as nucleic acids or polysaccharides into target cells.
  • WO 87/02989 describes the HIV TAT-3 protein and plasmids which have nucleic acid sequences coding for this protein. It is disclosed that the recombinant TAT-3 protein can be used for the diagnosis and therapy of HIV infections.
  • the transformation processes described in the context of gene therapy have the disadvantage of comparatively low efficiency.
  • the number of transformed cells necessary for a gene therapy promising approach is difficult or impossible to achieve.
  • the described methods also frequently have the disadvantage that the expression rate in the transformed cells is not high enough to be expected to have a therapeutic effect. It has proven to be particularly disadvantageous that some tissues or organs such as the brain are difficult to reach for metabolic products and, because of the blood / brain barrier, cannot be supplied with proteins by other organs. Somatic gene therapy is particularly problematic in such tissues or organs.
  • the present invention is therefore based on the technical problem of providing means and methods which ensure the high transformation and expression rate of genes of interest which is necessary for a successful gene therapeutic method.
  • the present invention solves the technical problem on which it is based by providing a vector for gene therapy purposes, comprising at least one nucleotide sequence coding for a translocation sequence selected from the group consisting of a nucleotide sequence coding for the HSV VP22 protein (HSV-VP22) : Elliott and O'Hare Cell (1997) 88, 223-233), a nucleotide sequence encoding the HIV-TAT protein transduction domain and a nucleotide sequence encoding the Antennipedia peptide (Antennipedia: Derozzi et al., J. Biol. Chem. (1994) 269, 10444-10450, Helix der Ho eodomäne: RQIKIWFGNRRMKWKK), SEQ ID No. 4).
  • a vector for gene therapy purposes comprising at least one nucleotide sequence coding for a translocation sequence selected from the group consisting of a nucleotide sequence coding for the HSV VP22 protein (
  • such a vector is designed as a plasmid vector, viral vector or liposome.
  • a plasmid vector comprising operatively linked to one another in the 5 'to 3' direction at least one constitutively expressing promoter, the nucleotide sequence coding for at least one translocation sequence, a NotI cloning site for the insertion of at least one nucleotide sequence which is useful in gene therapy and a polyadenylation site.
  • a plasmid vector is preferably provided for gene therapy purposes, the translocation sequence comprising the 11 amino acids YGRKKRRQRRR (SEQ ID No. 2) of the naturally occurring HIV-TAT lead peptide.
  • the translocation sequence comprises the 11 amino acids YARAAARQARA (SEQ ID No. 5) of an HIV-TAT lead peptide modified by targeted amino acid exchanges.
  • a plasmid vector for gene therapy purposes is preferably provided, which is referred to as pCURE (FIG. 1), comprising in operative linkage and in 5 'to 3' orientation at least one constitutively expressing promoter, at least one coding for a ribosome binding site (RBS) Nucleotide sequence, at least one nucleotide sequence encoding the HIV-TAT lead peptide, in particular encoding the 11 amino acids YGRKKRRQRRR (SEQ ID No. 2), an NotI cloning site for the insertion of a nucleotide sequence which is useful for gene therapy, in particular a gene therapy-meaningful gene site, and a polyaden ,
  • RBS ribosome binding site
  • the plasmid vectors according to the invention are characterized by a translocation sequence, in particular a nucleotide sequence coding for HIV-TAT leader peptide sequence, which is linked directly and seamlessly in reading frame to a nucleotide sequence coding for example a therapeutically meaningful protein or protein fragment, so that in the course of the transcription and translation in particular a HIV-TAT leader peptide sequence or a modified HIV Fusion protein having a TAT lead peptide sequence is formed in the target cell, that is to say the cell to be transformed or transformed.
  • a translocation leader sequence leader peptide sequence or translocation signal
  • 11 amino acids i.e.
  • the protein transduction domain of the HIV-TAT protein which is preferably provided according to the invention, surprisingly enables the fusion protein formed in a target cell to be exported from the transformed cell and imported into at least one another cell, especially crossing the blood-brain barrier. It was surprisingly found that the translocation property of a modified HIV-TAT protein transduction domain, in particular with an amino acid sequence as shown in SEQ ID No. 5, as a leading peptide improves even further compared to the naturally occurring protein-transduction domain of the HIV-TAT protein is.
  • the fusion protein encoded by the vector according to the invention is therefore suitable for intercellular transport.
  • the use of the plasmid vector according to the invention also leads to an increased number of transformed cells with intact protein, each with DNA-transformed cell, according to the invention.
  • the plasmid vector according to the invention is extremely small and can therefore also be large and / or record several genes or gene segments that are useful in gene therapy.
  • the insertion of the genes or gene segments which are meaningful in gene therapy is carried out by means of the inventively preferred, that is to say only once in the vector, that is to say “unique” NotI interface, which lies immediately behind the nucleotide sequence coding for the leading peptide or overlaps with it.
  • plasmid is provided with developmental or tissue-specific or regulatable regulatory elements, for example promoters or enhancers, which are a multiple cloning site are inserted into the vector.
  • developmental or tissue-specific or regulatable regulatory elements for example promoters or enhancers, which are a multiple cloning site are inserted into the vector.
  • the invention in a particularly preferred embodiment, it is provided to provide a multiple cloning site for the insertion of at least one regulatory element in the plasmid vector according to the invention, in particular this - in the 5 'to 3' direction - between a constitutively expressing promoter and a ribosome binding site insert le.
  • the constitutively expressing is the CMV promoter.
  • the translocation sequence comprises a modified amino acid sequence which results from the amino acid sequence SEQ ID No. 2 by addition, deletion or exchange of at least one amino acid, preferably ⁇ amino acids.
  • the amino acids glycine, lysine and / or arginine are replaced by the amino acid alanine.
  • the plasmid vector is preferred, wherein the translocation sequence comprises a modified amino acid sequence which results from the amino acid sequence SEQ ID No. 5 by addition, deletion or exchange of at least one amino acid, preferably from one to five amino acids.
  • the plasmid vector preferably has a nucleotide sequence functioning as an “N-linker”, which contains the nucleotide sequence coding for a translocation sequence.
  • the nucleotide sequence functioning as an “N-linker” comprises the nucleotide sequence according to SEQ ID No. 12.
  • the plasmid vector according to the invention contains a nucleotide sequence which functions as a “C-linker”, in which the nucleotide sequence coding for the translocation sequence contains is.
  • the nucleotide sequence functioning as a "C-linker” comprises the nucleotide sequence SEQ ID No. 13.
  • the translocation sequence is preferably always fused to the N-terminus of a nucleotide sequence that is useful in gene therapy.
  • sense - Full nucleotide sequences such as enzymes must retain the native N-terminus, either because they are only involved in the enzymatic activity in this unfused conformation or because they themselves carry specific transport signals, for example for import into the cell nucleus or into the mitochondia or for export to the extracellular matrix, in which case a cleavage of the leading peptide sequences after passage through the corresponding membrane is possible or even necessary.
  • nucleotide sequences which are useful in gene therapy such as enzymes, have a functional C-terminus which is used to maintain d the catalytic properties must not be blocked.
  • the N-linkers and C-linkers according to the invention described above were constructed as an optional component of the plasmid vector according to the invention.
  • For encoding proteins with either N- or C-terminal protein transduction domains for cloning Domain for cloning appropriate nucleotide sequences which are useful in gene therapy into the Not I interface of the plasmid vector according to the invention.
  • two versions of therapy plasmids are therefore preferably provided.
  • pCURE2C on the other hand pCURE2N ( Figure 2).
  • the term “gene therapy purpose” is understood to mean that the vector according to the invention, in particular plasmid vector, can be used for any gene therapy purposes, in particular for the introduction of foreign or endogenous nucleic acid sequences, in particular DNA sequences target cells.
  • any cells of the human or animal body for example a mammalian body, can be understood as target cells. These can be embryonic, stem, body or germline cells of any stage of development.
  • the invention therefore also relates to the use of the vector, in particular plasmid vector, both for somacell gene therapy and for germline gene therapy.
  • the invention also covers the use of the vector, in particular plasmid vector, for purposes other than gene therapy, for example for research purposes or for genetic diagnostic purposes.
  • operatively linked to one another is understood to mean that the linked elements are linked to one another in such a way that they can interact as intended, for example that operatively linked transcription elements ensure correct transcription.
  • Operatively linked transcription and translation elements enable correct expression, that is to say in particular transcription and translation, to form a functional translation product.
  • nucleotide sequences are understood, for example also genes, gene segments or other structural genome regions, the insertion of which into a target cell makes sense from a therapeutic point of view.
  • the nucleotide sequences to be inserted, in particular genes, can be endogenous or Exogenous to the target cell These can be nucleotide sequences which serve to complement or correct gene defects in the body being treated, but can also be understood to mean one or more gene sections which serve to switch off target genes in target cells.
  • Nucleotide sequences, in particular genes or gene segments, which are useful in gene therapy can also be antisense constructs which serve to inhibit transcription in the target cell and thus prevent or reduce the expression of certain proteins.
  • Genes or gene segments suitable for insertion into the present plasmid vector can of course also be protein-coding or non-protein-coding regions.
  • gene therapy will be under meaningful proteins understood gene products that are expressed in natural form, ie wild-type form, or modified form in target cells after insertion by means of genetic engineering methods.
  • Proteins of this type which are useful in gene therapy can be any proteins which, for example, occur in defective form in the cell or are not expressed there at all and can be introduced into the cell by means of gene therapy, but can also be proteins which are not naturally present in the target cell occur, but are nevertheless therapeutically desirable there. Such proteins can also be designed as protein fragments or fusion proteins and optionally have modifications, for example post-translational modifications. Of particular interest are genes which code for proteins which are absent in the target cell, are present in reduced amounts or in mutant form. Such proteins can include, in particular, hormones, growth factors, enzymes, lymphokines, cytokines, receptors and the like. In particular, it can be factor VIII, tPA or the molybdenum cofactor.
  • Molybdenum cofactor deficiency is a severe neurological disease that has not yet been treated and is ultimately fatal.
  • the smallest amounts of intact cofactor and thus also of biosynthesis enzymes are sufficient for a clinically unremarkable phenotype.
  • the main synthesis site is the liver, which is relatively easy to reach. Because of the procedure according to the invention, the enzymes formed here can be used using the set translocation signals are exported and also recorded by the brain.
  • the present invention therefore also relates to methods for the treatment of molybdenum cofactor deficiency and molybdenum cofactor deficiency diseases, such as the sulfite oxidase deficiency or the xanthine oxidase deficiency.
  • genes to be inserted are genes for hemoglobin, interleukin-1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, GM-CSF, G-CSF, M-CSF, human growth factor , Insulin, factor IX, LDL receptors, tumor necrosis factor, PDGF, EGF, NGF, IL-lra, EPO, TPO, beta-globin and biologically active muteins of these proteins.
  • nucleotide sequences are also provided according to the invention in the plasmid vector according to the invention, which code therapeutically useful proteins for the treatment of cystic fibrosis (cystic fibrosis of the lungs).
  • the present invention therefore also relates to a method for the treatment of cystic fibrosis.
  • the plasmid vector according to the invention contains the constitutive expressing promoter, the human beta-actin promoter, which in particular does not include an intron.
  • the human beta-actin promoter comprises the nucleotide sequence SEQ ID No. 10. Ent- speaking of this variant of the promoter region according to the invention, this simplest promoter structure without intron is referred to as plasmid vector pCURE2basic.
  • the plasmid vector has an expression enhancer, in particular an enhancer, particularly preferably the CMV enhancer.
  • the constitutively expressing promoter comprises in the 5 'to 3' direction a nucleotide sequence coding the CMV enhancer and the human beta-actin promoter.
  • the nucleotide sequence encoding the CMV enhancer comprises the nucleotide sequence SEQ ID No. 9.
  • the human beta-actin promoter comprises its native intron.
  • the plasmid vector according to the invention thus provided is referred to as pCURE2natin.
  • the human beta-actin promoter contained in the plasmid vector according to the invention comprises a shortened intron, the native 5 'and 3' splice sites and a shortened "stuffer ⁇ fragment.
  • the shortened intron of the human beta-actin promoter additionally comprises a nucleotide sequence coding for the SV40 enhancer.
  • the “stuffer” fragment is preferably shortened to such an extent that it only comprises the “branch site”.
  • the “stuffer” fragment is shortened by 700 to 800 bp; the staged fer fragment shortened by 761 bp.
  • the plasmid vectors according to the invention thus provided are referred to as pCURE2minin (containing the shortened intron) or pCURE2enhin (containing the shortened intron and the SV40 enhancer).
  • BGHpA BGH polyadenylation signal
  • the polyadenylation site is particularly preferably the BGH polyadenylation signal comprising the nucleotide sequence SEQ ID No. 6.
  • a ribosome binding site (RBS) with a start codon is located in the 5 'to 3' direction after the constitutively expressing promoter and immediately before the nucleotide sequence encoding a translocation sequence.
  • a multiple cloning site for the insertion of at least one regulatory element is preferably located in the plasmid vector according to the invention in the 5 'to 3' direction after the constitutively expressing promoter and before the nucleotide sequence coding for a translocation sequence.
  • the at least one regulatory element is a tissue-specific promoter.
  • the invention provides that the plasmid vector according to the invention contains at least one resistance gene, in particular a bacterial resistance gene.
  • this bacterial resistance gene is the amp R gene for ampicilin resistance.
  • the bacterial resistance gene is a kan R gene for kanaminicin resistance.
  • the kan R gene preferably comprises the nucleotide sequence SEQ ID No. 7.
  • the invention provides that the at least one resistance gene has at least one interface for linearizing and / or inactivating the resistance gene.
  • the plasmid vector has at least one origin of replication for plasmid cultivation, particularly in bacteria.
  • the origin of replication comprises the nucleotide sequence SEQ ID No. 8.
  • the plasmid vector is preferably derived from the known vector pcDNA 3.1 (-) and is in particular 3.4 kbp in size (FIG. 1).
  • the plasmid vector according to the invention is only 2.8 kbp in size and particularly preferably comprises the nucleotide sequence SEQ ID No. 11 (FIG. 2).
  • the invention also relates to host cells or cells of a cell culture containing at least one plasmid vector of the present invention.
  • a host cell can be, inter alia, a bacterial cell, a yeast cell, an animal cell, for example a mammalian or insect cell or a human cell.
  • the invention also relates to methods for the genetic modification of a cell, for example an animal or human cell, comprising contacting the cell with a vector, in particular plasmid vector, according to the present invention under conditions which include an uptake of the vector, in particular plasmid vector allow the cell, especially the cell's genome.
  • the invention therefore also relates to methods for producing genetically modified cells, the cells to be genetically modified being brought into contact with a vector, in particular a plasmid vector, of the present invention and being transiently or stably transformed.
  • the invention also relates to the use of a vector, in particular plasmid vector, of the present invention for the production of a preparation, in particular a pharmaceutical preparation for gene therapy, in particular somatic gene therapy.
  • the invention therefore also relates to preparations, in particular pharmaceutical preparations, containing at least one vector, in particular plasmid vector, of the present invention, optionally together with a pharmaceutically acceptable carrier. Further advantageous embodiments of the invention result from the subclaims.
  • SEQ ID No. 1 the 33 nucleotides encoding the HIV-TAT lead peptide sequence (SEQ ID No. 2),
  • SEQ ID No. 2 the 11 amino acids of the naturally occurring HIV-TAT lead peptide sequence
  • SEQ ID No. 3 the nucleotide sequence containing 49 nucleotides of the region of pCU-RE comprising the RBS, the HIV-TAT region and the NoTl cloning site,
  • SEQ ID No. 4 the amino acid sequence of the helix of the home domain from Antennipedia
  • SEQ ID No. 5 the 11 amino acids of the modified, non-naturally occurring HIV-TAT lead peptide sequence
  • SEQ ID No. 6 the nucleotide sequence of the BGH polyadenylation signal containing 235 nucleotides
  • SEQ ID No. 7 the nucleotide sequence of the kanamicin resistance gene kan R containing 1189 nucleotides
  • SEQ ID No. 8 the nucleotide sequence of the origin of replication containing 661 nucleotides
  • SEQ ID No. 9 the nucleotide sequence of the CMV enhancer containing 348 nucleotides
  • SEQ ID No. 10 the nucleotide sequence of the beta-actin promoter containing 377 nucleotides
  • SEQ ID No. 11 the nucleotide sequence of the plasmid vector pCURE2basic according to the invention containing 2810 nucleotides (without a cloned nucleotide sequence which makes sense in terms of gene therapy),
  • SEQ ID No. 12 shows the nucleotide sequence containing 40 nucleotides of the “N-linker” encoding the modified HIV-TAT leading peptide sequence (SEQ ID No. 5), consisting of synthetic oligonucleotides 2NF and 2NR and
  • SEQ ID No. 13 contains the nucleotide sequence containing the 37 nucleotides of the “C-linker” encoding the modified HIV-TAT lead peptide sequence (SEQ ID No. 5), consisting of synthetic oligonucleotides 2CF and 2CR.
  • FIG. 1 shows a graphic representation of the plasmid pCURE
  • FIG. 2 shows a graphic representation of the plasmid pCURE2basic
  • FIG. 3 shows an in situ coloring of a brain half transformed according to the invention and a control
  • FIG. 4 thin sections of the liver and brain (each negative control and transformed according to the invention).
  • FIG. 5 shows thin sections of a brain transformed according to the invention after intrahepatic injection of pCURE2Cbasic-lacZ (FIG. 5A) and thin section of the brain of an untreated control animal (FIG. 5B),
  • FIG. 6 shows thin sections of a lung with bronchial epithelium transformed according to the invention after intrahepatic injection of pCURE2Cbasic-lacZ (FIG. 6A) and thin section of the lung of an untreated control animal (FIG. 6B).
  • the expression vector pcDNA 3.1 (-) from Invitrogen (cat. No. V 795-20) was cleaved with EcoRV and Nael. The plasmid was then religated and the nucleotide sequence according to SEQ ID No. 3 was inserted into the NotI site.
  • FIG. 1 graphically represents the plasmid pCURE in PVU I linearized form (from left to right in 5 'to 3' orientation).
  • the abbreviations used in FIG. 1 mean: P CMV CMV promoter for cell type-independent expression (source: pcDNA3.1 (-))
  • MCS multiple cloning site for tissue-specific promoters NhelU, Pmel, Drall, Apal, Xbal, Xhol
  • TAT TAT leader sequence as translocation signal for intercellular transport
  • Notl insertion site for, for example, therapeutically useful cDNA
  • pMBl origin of replication (pUC-derived) for plasmid cultivation in bacteria
  • pCUREl has a size of 3.4 kbp without inserted DNA.
  • FIG. 1 shows that a multiple cloning site MCS is arranged between P CM, ie the CMV promoter, and the ribosomal binding site. In the 3 'direction of which follow a TAT leader sequence, a Notl insertion site and the SV40pA polyadenylation site.
  • pCURE-lacZ was constructed by cloning the lacZ gene from E. coli into the NotI site of pCURE ( Figure 1).
  • the resulting plasmid pCURE-lacZ contains amino acids 8 to 1023 of E. coli beta-galactosidase, which convert Xgal to a blue dye.
  • This catalytic domain lies in the reading frame behind the HIV-TAT translocation leader sequence, which enables intercellular transport.
  • pCURE-lacZ was isolated on a mg scale, sterile and pyrogen-free from the E.coli strain JM109 (Qiagen endomaxiprep kit) and after concentration determination adjusted to 150 mM phosphate buffer, pH 7.0 (this buffer also serves as an injection solution for the Control mice).
  • mice were injected with 50 ⁇ g pCURE-lacZ in 50 ⁇ l phosphate buffer directly into the liver. After 96 hours, the animals were sacrificed and various organs were removed. Brain, liver, heart and lungs were frozen in liquid nitrogen and stored at -70 ° C until further analysis. The above-mentioned organs were incubated in Xgal staining solution (Stratagene Xgal in si tu detection kit) at 37 ° C overnight and used after embedding in paraffin for thin sections of 10-40 ⁇ m.
  • Xgal staining solution Stratagene Xgal in si tu detection kit
  • FIG. 3 shows brain halves stained in total after Xgal incubation. Left: injection of 50 ⁇ g pCURE-lacZ. Right: injection of 50 ⁇ l phosphate buffer (negative control).
  • FIG. 4 shows paraffin-fixed thin sections of the corresponding organs, a) and b) liver tissue: a) negative control b) injection of pCURE-lacZ. c) and d) brain: c) negative control d) injection of pCURE-lacZ.
  • vectors according to the invention were successfully transferred into the tissue, expressed there and the gene products were also transported into non-transfected organs, in particular the brain.
  • Example 4 The plasmids pCURE2basic, pCURE2nativ, pCURE2minin and pCURE2enhin
  • the CMV promoter present on the therapy plasmid pCURE according to Example 1 is replaced by various variants of the human beta-actin promoter. Both promoters are expressed ubiquitously, i.e. in all organs.
  • the human beta actin promoter is first used using genomic clones and PCR technologies for use in the therapy plasmids.
  • the human beta-actin gene is ubiquitously expressed for life, thus bypassing promoter inactivation.
  • the human beta-actin promoter is used according to the invention in a total of four different variants of the promoter area:
  • CMV enhancer + beta-actin promoter + beta-actin intron in which the internal intron sequence is replaced by the SV40 enhancer element + BGHpA (enhancer intron)
  • the "pure" promoter area contains the so-called "CAT” and “TATA” boxes for transcription initiation and represents the smallest of the four possibilities.
  • this version contains, in addition to the promoter, an intron in front of the start codon or the coding sequence.
  • the intron consists of a 5 'and 3' splice point and an internal “step fer “fragment, which only provides a certain distance between the two splice sites. Since the intron does not contain a coding sequence, it can only have regulatory properties at the level of transcription.
  • the mini-intron contains the native 5 'and 3' splice points, but the "stuffer” is greatly shortened in order to keep the size of the total plasmid small.
  • the "stuffer” is shortened so that the so-called " branch site "is still included.
  • the" stuffer "of the mini-intron is shortened by 761 bp.
  • the enhancer intron corresponds to the mini intron plus the SV40 enhancer area, which in turn serves as a “stuffer” and thus takes into account a requirement for the distance between the two splice points.
  • the SV40 enhancer area which in turn serves as a “stuffer” and thus takes into account a requirement for the distance between the two splice points.
  • it fulfills the passive native “ stuffer "an expression enhancement function. After the transcription, this previously useful area (core import and spacer) is no longer needed and, like the native intron, is spliced out.
  • the promoter area consisting of the CMV enhancer (native sequence from the cytomegalovirus, GenBank M60321), different parts of the human beta actin promoter (native sequence from the human genome, Genbank AC006483), in one of the variants described above from the SV40 enhancer element (na- tive sequence from Simian Virus 40, GenBank NC001669), together with the BGH polyadenylation site (native sequence from the bovine genome, GenBank J00008) forms the expression cassette of the therapy plasmid.
  • This also consists of an origin of replication (ori) for plasmid propagation in bacteria, in particular the native sequence from pUC9 (identical to pUCl3 GenBank L09130) and in particular a kanamycin resistance (native from pACYC177, GenBank X06402) for antibiotic selection in bacteria.
  • origin of replication for plasmid propagation in bacteria, in particular the native sequence from pUC9 (identical to pUCl3 GenBank L09130) and in particular a kanamycin resistance (native from pACYC177, GenBank X06402) for antibiotic selection in bacteria.
  • the kanamycin resistance has the further advantage over the ampicillin resistance used in pCURE (example 1) that its use is also approved for clinical trials from phase III. All of the sequence elements of pCURE2 were made individually. A precursor plasmid such as pcDNA3.1 was therefore not used as in pCURE.
  • pCURE2basic contains the simplest promoter structure a (no intron).
  • pCURE2natin includes Version b (native intron).
  • pCURE2minin includes version c (mini-intron).
  • pCURE2enhin contains version d (enhancer intron).
  • the four variants of pCURE2 described above are each constructed optionally for the coding of proteins with N- as well as with C-terminal protein transduction domains after the corresponding coding sequences have been cloned into the unique Notl interface. This results in a total of 8 options and therapy plasmids:
  • the basal therapy plasmid pCURE2basic with a total of 8 variants is shown in FIG. 2.
  • kan R The sequence for kanamycin resistance (kan R ) is amplified from pACYC177 PCR.
  • the origin of replication (ori) is amplified from pUC9 by means of PCR.
  • the CMV enhancer sequence which was amplified from pCURE (example 1) by means of PCR, is incorporated into this, the PCR primers being selected according to the invention such that the emergency (downstream) only in the 3 ⁇ direction from the enhancer (downstream) Interface is restored and thus remains unique.
  • the BGHpA is amplified from genomic bovine DNA PCR and installed after the enhancer in the unique Notl interface, the PCR primers having been selected according to the invention such that only the Notl interface before the BGHpA (upstream) is restored.
  • various areas of the human beta-actin promoter or the SV40 enhancer region are installed between the enhancer and the polyadenylation site. This installation is carried out according to the principle set forth above, wherein interfaces are so incorporated into the PCR primers that only the 3 ⁇ -NotI interface (downstream) restorers is riert and thus the plasmid can be linearized again with Notl for the next ligation.
  • the N- or C-linkers according to the invention are installed, each of which has been completely synthesized.
  • the N-linker according to the invention provides the fusion protein with a N-terminal Proteintranslokationsdomäne (PTD), the 3 ⁇ -NotI interface is preserved for installation of further sequences.
  • the C-linker provides the fusion protein with a C-terminal PTD, the 5 -NotI interface being retained.
  • the lacZ cassette was isolated for pCURE2Nbasic-lacZ from pCURE-lacZ (Example 2) with restriction enzymes or for PCR for pCURE2Nbasic-lacZ from pCURE-lacZ (Example 2).
  • mice Two-day-old mice (wild type) were injected intrahepatically with 50 ⁇ g of the isolated plasmid vector according to the invention containing the lacZ gene in 50 ⁇ l of a 150 mM phosphate buffer with pH 7.0. After 7 days, the animals were sacrificed, the organs removed and, after Xgal staining, paraffin sections of the lungs and brain were made. At the same time, non-injected control animals of the same age were also paraffin sections from Brain and lungs made. The Xgal staining was carried out according to Example 3. All enlargements of the paraffin sections are a hundred times and without counterstaining.
  • FIGS. 5A and 5B show completely colored brain halves after Xgal incubation.
  • FIG. 5A After injection of 50 ⁇ g of the plasmid vector.
  • Figure 5B after injection of 50 ul phosphate buffer (negative control).
  • the brain sections show on the right the heavily stained choroid plexus and on the left the stained neurons of the cerebral cortex. It can be clearly seen that in the animals treated with the plasmid vector according to the invention, the neurons are colored blue; there the lacZ gene was transformed and expressed according to the invention.
  • the plasmid vector according to the invention is suitable for the somatic gene therapy of brain neurons.
  • the blood-brain barrier is - particularly surprisingly - overcome by the fusion proteins according to the invention.
  • Figures 6A and 6B show the results for the lungs: In the lung sections, a bronchus with a strongly stained epithelium can be seen centrally. Due to the lack of staining in the negative control, this structure is difficult to see there. The specific staining of the bronchial pithels shows that the lacZ gene transformed into the bronchial epithelium with the plasmid vector according to the invention is expressed.
  • the specific staining of the bronchial epithelium makes the use of the plasmid vector according to the invention particularly suitable for treating the cystic fibrosis of the lungs (cystic fibrosis).

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un vecteur particulièrement adapté à la thérapie génique somatique, des préparations pharmaceutiques contenant ce vecteur et ses utilisations. Ledit vecteur comporte au moins une séquence nucléotidique codant pour une séquence de translocation, sélectionnée dans le groupe constitué de séquences nucléotidiques codant pour la protéine HSV VP22, d'un domaine de translocation HIV-Tat et d'un peptide <i>Antennapedia</i>.
PCT/EP2002/006234 2001-06-15 2002-06-07 Vecteur et son utilisation dans des procedes de therapie genique Ceased WO2002102417A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2001128832 DE10128832A1 (de) 2001-06-15 2001-06-15 Vektor und dessen Verwendung in gentherapeutischen Verfahren
DE10128832.8 2001-06-15

Publications (1)

Publication Number Publication Date
WO2002102417A1 true WO2002102417A1 (fr) 2002-12-27

Family

ID=7688242

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/006234 Ceased WO2002102417A1 (fr) 2001-06-15 2002-06-07 Vecteur et son utilisation dans des procedes de therapie genique

Country Status (2)

Country Link
DE (1) DE10128832A1 (fr)
WO (1) WO2002102417A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007132481A3 (fr) * 2006-05-12 2008-06-26 Bharat Biotech Int Ltd Nouvelles molécules thrombolytiques et procédé associé
US8298816B2 (en) 2003-12-03 2012-10-30 Chugai Seiyaku Kabushiki Kaisha Expression systems using mammalian beta-actin promoter

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055684A2 (fr) * 2001-01-09 2002-07-18 Univ Iowa Res Found Proteines a ptd modifie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO1999029721A1 (fr) * 1997-12-10 1999-06-17 Washington University Systeme anti-pathogene et procedes d'utilisation
IL142869A0 (en) * 1998-11-13 2002-03-10 Cyclacel Ltd Transport vectors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055684A2 (fr) * 2001-01-09 2002-07-18 Univ Iowa Res Found Proteines a ptd modifie

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HO A ET AL: "Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 61, 15 January 2001 (2001-01-15), pages 474 - 477, XP002179150, ISSN: 0008-5472 *
KWON H Y ET AL: "Transduction of Cu,Zn-superoxide dismutase mediated by an HIV-1 Tat protein basic domain into mammalian cells", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 485, no. 2-3, 24 November 2000 (2000-11-24), pages 163 - 167, XP004337789, ISSN: 0014-5793 *
PHELAN A ET AL: "INTERCELLULAR DELIVERY OF FUNCTIONAL P53 BY THE HERPESVIRUS PROTEINVP22", NATURE BIOTECHNOLOGY, NATURE PUB. CO, NEW YORK, NY, US, vol. 16, no. 5, May 1998 (1998-05-01), pages 440 - 443, XP000979081, ISSN: 1087-0156 *
SCHWARZE S R S R ET AL: "In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 21, no. 2, February 2000 (2000-02-01), pages 45 - 48, XP004189118, ISSN: 0165-6147 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8298816B2 (en) 2003-12-03 2012-10-30 Chugai Seiyaku Kabushiki Kaisha Expression systems using mammalian beta-actin promoter
WO2007132481A3 (fr) * 2006-05-12 2008-06-26 Bharat Biotech Int Ltd Nouvelles molécules thrombolytiques et procédé associé
GB2451044A (en) * 2006-05-12 2009-01-14 Bharat Biotech Int Ltd Novel thrombolytic molecules and a process therefor
JP2009536821A (ja) * 2006-05-12 2009-10-22 バハラ バイオテック インターナショナル リミテッド 新規血栓溶解分子及びその製造法
GB2451044B (en) * 2006-05-12 2010-06-16 Bharat Biotech Int Ltd Novel thrombolytic molecules and a process therefore

Also Published As

Publication number Publication date
DE10128832A1 (de) 2003-02-06

Similar Documents

Publication Publication Date Title
Struhl Near-reciprocal phenotypes caused by inactivation or indiscriminate expression of the Drosophila segmentation gene ftz
DE69024440T2 (de) Verfahren zum spezifischen ersetzen einer genkopie, die sich in einem rezeptorengenom befindet, durch genintegration
EP1681355B1 (fr) Recombinaison avec une séquence spécifique d&#39;ADN dans des cellules eukaryotes
DE69827507T2 (de) Trimerisierendes modul
DE69325794T2 (de) Humanes serum albumin, herstellung und verwendung
EP0986644B1 (fr) Production d&#39;erythropoietine par activation genique endogene avec des promoteurs viraux
CN119391700A (zh) 利用人工构建rna编辑酶进行rna定点编辑及相关应用
DE69232544T2 (de) Vitamin-k-abhängige carboxylase
DE3687141T2 (de) Verfahren zur herstellung von peptiden.
DE10235248A1 (de) Fusionsprotein mit verstärkter in vivo-Aktivität von Erythropoietin
EP0544292A2 (fr) Méthode d&#39;introduction d&#39;acides nucléiques dans des cellules
CN111718418B (zh) 一种增强基因编辑的融合蛋白及其应用
CH676990A5 (fr)
WO2002102417A1 (fr) Vecteur et son utilisation dans des procedes de therapie genique
DE60130465T2 (de) Mutierte muskelspezifische enhancer
DE69033772T2 (de) Verbesserte plasmidvektoren für zelluläre schleimpilze der gattung dictyostelium
DE19943383B4 (de) Regulatorische Sequenzen und Expressionskassetten für Hefen
DE60024596T2 (de) Sequenzen zur verbesserung der sekretionseffizienz von nicht-sekretierten proteinen in säugetier- und insektenzellen
EP1000167B2 (fr) Production de proteines mutantes humaines dans des cellules humaines par recombinaison homologue
DE10155862A1 (de) Produktion von rekombinanten Antikörpern mittels Fusion mit Elastin-ähnlichen Peptiden
WO2003070931A2 (fr) Techniques de recombinaison d&#39;adn a des sites specifiques
EP0950713A2 (fr) Vecteur recombinant adenoviral pour le transfert de gènes
DE3485883T2 (de) Rekombinante materialien und verfahren zur herstellung von menschliche konnektive gewebe aktivierende peptide iii und deren analoge.
EP1068237A1 (fr) Cassette d&#39;expression du recepteur des cellules t
DD298269A5 (de) Verfahren zur herstellung von fremdproteinen in tierischen zellen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: FESTSTELLUNG EINES RECHTSVERLUSTES NACH REGEL 69(1) EPUE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP